MWNA
PMVP icon

Marshall Wace North America’s PMV Pharmaceuticals PMVP Stock Holding History

Marshall Wace North America’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$204K Buy
+6,848
New +$219K ﹤0.01% 1321

Other funds holding PMVP

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Marshall Wace North America's PMVP Position: Q3 2021 in Review

Marshall Wace North America opened a new position in PMV Pharmaceuticals (PMVP) in Q3 2021: 6,848 shares worth $204K. The stake represents ﹤0.01% of the portfolio and ranks #1321 among its holdings.

92 funds tracked by Wall St. Rank hold PMVP as of Q3 2021.

  • Marshall Wace North America held 6,848 shares of PMV Pharmaceuticals worth $204K as of Q3 2021.
  • PMV Pharmaceuticals was a new Marshall Wace North America position in Q3 2021.
  • PMV Pharmaceuticals made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1321 holding.
  • 92 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.